Rankings
▼
Calendar
AMRX Q2 2018 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q2 2018 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$414M
+59.2% YoY
Gross Profit
$178M
43.1% margin
Operating Income
-$181M
-43.8% margin
Net Income
-$219M
-53.0% margin
EPS (Diluted)
$-1.73
QoQ Revenue Growth
+50.4%
Cash Flow
Operating Cash Flow
-$99M
Free Cash Flow
-$119M
Stock-Based Comp.
$160M
Balance Sheet
Total Assets
$4.5B
Total Liabilities
$3.6B
Stockholders' Equity
$495M
Cash & Equivalents
$62M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$414M
$260M
+59.2%
Gross Profit
$178M
$124M
+44.1%
Operating Income
-$181M
$45M
-505.9%
Net Income
-$219M
$37M
-686.0%
Revenue Segments
Oseltamivir
$40M
23%
Diclofenac Sodium Gel
$32M
19%
Yuvafem-Estradiol
$31M
18%
Aspirin;Dipyridamole ER Capsul
$28M
16%
Rytary Family
$21M
12%
Epinephrine Auto-Injector Family (Generic Adrenaclick)
$19M
11%
← FY 2018
All Quarters
Q3 2018 →